After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.

After Affymetrix's shareholders approved the acquisition, Thermo Fisher was able to close the deal for a total purchase price of $1.3 billion.

Initially studying pancreatic tissue, the team also linked their findings to methylation patterns in blood, suggesting the possibility of developing a non-invasive test.

The Dutch informatics firm will use the funds to further develop its cloud-based platform to help customers process large volumes of genomic data. 

The company attributed increases to both its revenues and expenses to the 2014 acquisition of RedPath Integrated Pathology and two tests from Asuragen.

The researchers will use a new humanized mouse model to obtain genetic information at different life stages of the parasite.

FDA allows the use of an investigational test to screen blood samples for the Zika virus.

In a poll, European researchers want the UK to remain in the European Union, Nature says.

A year after its official launch, the Open Humans project is ready to grow and engage more research teams who want to access its data.

Through a meta-analysis, a consortium linked maternal smoking during pregnancy to differential methylation sites in infant genomes.

The new genome assembly for a western lowland gorilla named Susie has fewer gaps than a prior assembly produced from short reads and Sanger sequencing.

The new center will help accelerate personalized medicine efforts and support a collaborative research ecosystem in Europe.

The partners will work on pilot projects that use novel analytical approaches to explore oncology molecular and imaging data.

The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring. 

Researchers have linked human lifespan to two genetic variants located near Alzheimer's disease- and lung cancer-associated genes.

In Nature this week: transcriptomic and epigenomic analysis of bat wing development, and more.

A researcher and entrepreneur writes that approaches that startups take can also help researchers identify real-world problems to study.

The results suggest PAM sites for all kinds of CRISPR systems are more complex than previously thought, even for well-studied systems like S. pyogenes.

GeneNews will also collaborate with the healthcare and management consulting firm to increase test adoption and improve revenue collection.

Researchers identified a common variant in a long non-coding RNA that may contribute to inflammation seen in patients diagnosed with celiac disease. 

OmniSeq has appointed Mark Gardner as its CEO and as a member of its board of directors. Gardner is currently vice president and general manager for Thermo Fisher Scientific's next generation clinical sequencing business. He will transition to his new role at OmniSeq in April. Prior to his work at Thermo Fisher, Gardner held senior management positions at McKinsey, GE Medical Systems, Invitrogen, and Life Technologies.

Lasergen has appointed Timothy Burcham as its CTO. He will help develop the firm's sequencing platform. Burcham has been a member of the firm's scientific advisory board since 2015, and previously spent time developing and launching sequencing systems at Applied Biosystems. The firm also plans to rearrange its board to accommodate three seats from Agilent and will add Steven Arnold, a management consultant who also serves on the board at Houston Methodist Research Institute and Texas Children's Hospital Cancer Center. 

The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.

Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

Researchers get together to develop a better genetic map of the Aedes aegypti mosquito, the New York Times reports.